Sun Pharma Advanced Research Company (Mid Cap) Share Target 2025, 2026 To 2035
|
Sun Pharma Advanced Research Company Limited |
|||
|
Price: ₹177.01 (-1.68%) | ||
| 52 Week Low: ₹170.21 52 Week High: ₹472.80 |
|||
| Market Capital: 7,257.93 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Sun Pharma Advanced Research Company Share Price Target For 2025
- 1.1.1: Sun Pharma Advanced Research Company Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Sun Pharma Advanced Research Company Share Price Target For 2026
- 1.2.1: Sun Pharma Advanced Research Company Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Sun Pharma Advanced Research Company Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Sun Pharma Advanced Research Company Brief Company Overview
- 4: Sun Pharma Advanced Research Company Financial Performance
- 4.0.1: Is Sun Pharma Advanced Research Company A Good Buy For Long Term?
Sun Pharma Advanced Research Company, a Mid Cap company in the Drug Manufacturers - Specialty & Generic Industry with 28.1% profit margin.
To predict the Sun Pharma Advanced Research Company's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Sun Pharma Advanced Research Company Share Price Target For 2025
The line chart displays the monthly closing prices of Sun Pharma Advanced Research Company with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sun Pharma Advanced Research Company shares in 2025, see the table below.
Sun Pharma Advanced Research Company Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 226.9 (+28.18%) | Price Action: 22 Jul 2024 High |
| 2025 Target 2 | 224.65 (+26.91%) | Price Action: 25 Jul 2024 Low |
| 2025 Target 1 | 222.4 (+25.64%) | Price Action: 16 May 2024 High |
| Current Price | 177.01 | Sun Pharma Advanced Research Company's share price as of 21 Jan 2025 |
| Stop Loss 1 | 156.15 (-11.79%) | Price Action: Jul 2020 Low |
| Stop Loss 2 | 154.25 (-12.86%) | Price Action: Jun 2014 Low |
| Stop Loss 3 | 152.26 (-13.99%) | Price Action: Jul 2014 Low |
Short-Term Technical Outlook
Current Technical Position: Sun Pharma Advanced Research Company is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹193.89 serves as the nearest technical reference point.
Historical Returns: 3-month: -18.01% | 6-month: -22.88% | 1-year: -53.69%
Sun Pharma Advanced Research Company Share Price Target For 2026
The line chart displays the monthly closing prices of Sun Pharma Advanced Research Company with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sun Pharma Advanced Research Company shares in 2026, see the table below.
Sun Pharma Advanced Research Company Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 372.25 (+110.29%) | Price Action: 29 Feb 2024 High |
| 2026 Target 2 | 368.0 (+107.89%) | Price Action: 30 Jan 2024 Low |
| 2026 Target 1 | 363.5 (+105.35%) | Price Action: 09 Feb 2024 High |
| Current Price | 177.01 | Sun Pharma Advanced Research Company's share price as of 21 Jan 2025 |
| Stop Loss 1 | 127.9 (-27.75%) | Price Action: Chart |
| Stop Loss 2 | 126.62 (-28.47%) | Price Action: Chart |
| Stop Loss 3 | 124.34 (-29.76%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Sun Pharma Advanced Research Company is currently trading near its 52-week low of ₹170.21, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -53.69% | 3-year: -43.35% | 5-year: -9.13%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Sun Pharma Advanced Research Company Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹177.01 | ||
| 2025 | ₹204.59 | +15.58% | ₹207.66 |
| 2026 | ₹203.92 | -0.32% | ₹206.98 |
| 2027 | ₹216.42 | +6.12% | ₹219.67 |
| 2028 | ₹217.16 | +0.34% | ₹220.42 |
| 2029 | ₹228.96 | +5.43% | ₹232.39 |
| 2030 | ₹237.84 | +3.87% | ₹241.41 |
| 2031 | ₹252.32 | +6.08% | ₹256.10 |
| 2032 | ₹284.02 | +12.56% | ₹288.28 |
| 2033 | ₹304.12 | +7.07% | ₹308.68 |
| 2034 | ₹307.24 | +1.02% | ₹311.85 |
| 2035 | ₹330.24 | +7.48% | ₹335.19 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Sun Pharma Advanced Research Company Brief Company Overview
Overview of Sun Pharma Advanced Research Company Limited Sun Pharma Advanced Research Company Limited is a leading biopharmaceutical company dedicated to research and development of innovative pharmaceutical products. Founded in 2006 and headquartered in Mumbai, India, the...
company has a strong presence in India and internationally. Sun Pharma Advanced Research is renowned for its diverse product portfolio, with a focus on therapeutics for oncology, neurodegeneration, ophthalmology, dermatology, and immunology. Notable Products Elepsia XR (anti-epileptic) Xelpros (glaucoma treatment) Phenobarbital injection (neonatal seizures) Development Pipeline The company is committed to expanding its product range through ongoing research and development. Some key pipeline candidates include: SDN-037 (ocular surgery inflammation) PDP-716 (glaucoma) Vodobatinib (chronic myelogenous leukemia and Parkinson's disease) SCD-044 (psoriasis and atopic dermatitis) SCO-120 (breast cancer)Sun Pharma Advanced Research Company Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 7,257.93 Crore | Market valuation of Sun Pharma Advanced Research Company's shares. |
| Revenue (TTM) | 106.68 Crore | Total revenue generated by Sun Pharma Advanced Research Company over the past twelve months. |
| Net Income (TTM) | -363.41 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -763.21% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +28.14% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-89.4% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
4.28 | Company's total debt divided by total shareholder equity. |
| Total Debt | 14.21 Crore | Sum of Sun Pharma Advanced Research Company's current & long-term financial obligations. |
| Total Cash | 366.09 Crore | Total amount of liquid funds available to Sun Pharma Advanced Research Company. |
| Beta | 0.74 | Beta is less than 1 indicating that the Sun Pharma Advanced Research Company's price is less volatile than the market. |
Is Sun Pharma Advanced Research Company A Good Buy For Long Term?
Despite a recent revenue decline and a negative profit margin, Sun Pharma Advanced Research Company has historically delivered positive returns over the long term. With a revenue of 106.68 Crore, a net profit of -363.41 Crore, and a market cap of 7,257.93 Crore, the company's financials warrant caution. Its recent -89.4% revenue change compared to the previous quarter raises concerns. However, its past performance suggests potential for long-term growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
